Mary Wilson
Well-known member
April 6, 2021
DOI: 10.1056/NEJMc2103916
NicoleDoria?Rose,Ph.D., Mehul S. Suthar, Ph.D.
To the Editor: Interim results from a phase 3 trial of the Moderna mRNA-1273 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine indicated 94% efficacy in preventing coronavirus disease 2019 (Covid-19).1 The dura- bility of protection is currently unknown. We de- scribe mRNA1273-elicited binding and neutral- izing antibodies in 33 healthy adult participants in an ongoing phase 1 trial,2-4 stratified accord- ing to age, at 180 days after the second dose of 100 ?g (day 209).
Antibody activity remained high in all age groups at day 209. Binding antibodies, measured by means of an enzyme-linked immunosorbent assay against SARS-CoV-2 spike receptor?binding domain,2 had geometric mean end-point titers (GMTs) of 92,451 (95% confidence interval [CI], 57,148 to 149,562) in participants 18 to 55 years of age, 62,424 (95% CI, 36,765 to 105,990) in those 56 to 70 years of age, and 49,373 (95% CI, 25,171 to 96,849) in those 71 years of age or older. Nearly all participants had detectable ac- tivity in a pseudovirus neutralization assay,2 with 50% inhibitory dilution (ID50) GMTs of 80 (95% CI, 40 to 135), 57 (95% CI, 30 to 106), and 59 (95% CI, 29 to 121), respectively. ...
https://www.nejm.org/doi/pdf/10.1056/NEJMc2103916?articleTools=true
DOI: 10.1056/NEJMc2103916
NicoleDoria?Rose,Ph.D., Mehul S. Suthar, Ph.D.
To the Editor: Interim results from a phase 3 trial of the Moderna mRNA-1273 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine indicated 94% efficacy in preventing coronavirus disease 2019 (Covid-19).1 The dura- bility of protection is currently unknown. We de- scribe mRNA1273-elicited binding and neutral- izing antibodies in 33 healthy adult participants in an ongoing phase 1 trial,2-4 stratified accord- ing to age, at 180 days after the second dose of 100 ?g (day 209).
Antibody activity remained high in all age groups at day 209. Binding antibodies, measured by means of an enzyme-linked immunosorbent assay against SARS-CoV-2 spike receptor?binding domain,2 had geometric mean end-point titers (GMTs) of 92,451 (95% confidence interval [CI], 57,148 to 149,562) in participants 18 to 55 years of age, 62,424 (95% CI, 36,765 to 105,990) in those 56 to 70 years of age, and 49,373 (95% CI, 25,171 to 96,849) in those 71 years of age or older. Nearly all participants had detectable ac- tivity in a pseudovirus neutralization assay,2 with 50% inhibitory dilution (ID50) GMTs of 80 (95% CI, 40 to 135), 57 (95% CI, 30 to 106), and 59 (95% CI, 29 to 121), respectively. ...
https://www.nejm.org/doi/pdf/10.1056/NEJMc2103916?articleTools=true